Is Veeva Systems Inc. (VEEV) A Good Stock To Buy Now? - Insider Monkey

Vertical SaaS is having a moment on Wall Street — and it's worth paying attention to why, even if you have zero interest in buying stock.

Veeva Systems just got a fresh round of analyst attention as a "structurally advantaged" business. The reason analysts love it: Veeva built software specifically for life sciences, not a generic platform awkwardly bent to fit the industry. That specificity is the whole thesis. It's why pharma companies pay a premium and stay.

That same logic applies to your business, and it's the thing most CRM vendors won't tell you. Generic platforms are built for the median company. If your sales motion, your customer lifecycle, or your data model is even slightly different from the average — and it almost certainly is — you spend years fighting the software instead of running the business.

You've probably already lived this. A platform that looked flexible in the demo, locked you into its structure the moment you went live, and left you dependent on consultants to change anything meaningful. Switching platforms didn't fix it because the replacement had the same underlying problem: it was built for someone else.

The companies that stop losing that battle aren't the ones with the biggest budgets. They're the ones who stopped trying to make a generic tool fit a specific operation.

#CRM #SalesOperations #MidMarket #B2BSoftware #RevOps

Original Source

(VEEV) is a structurally advantaged vertical SaaS company and the software backbone of the global life sciences industry, spanning CRM, clinical trial ...